G Vassal
Overview
Explore the profile of G Vassal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
1245
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Di Carlo D, Annereau M, Vignes M, Denis L, Epaillard N, Dumont S, et al.
Eur J Cancer
. 2024 Dec;
216:115165.
PMID: 39700833
Introduction: H3K27-altered diffuse midline gliomas (DMG) have limited therapeutic options and a very poor prognosis. Encouraging responses were observed in early clinical trials with ONC201. As ONC201 was unavailable in...
2.
Di Carlo D, Annereau M, Yoldjian I, Vassal G, Grill J
Ann Oncol
. 2023 Jul;
34(9):826-827.
PMID: 37423297
No abstract available.
3.
Vassal G, Kozhaeva O, Griskjane S, Arnold F, Nysom K, Basset L, et al.
Ann Oncol
. 2021 Jan;
32(4):560-568.
PMID: 33388384
Background: Essential anticancer medicines are an indispensable component of multidisciplinary treatment of paediatric malignancies. A European Society for Medical Oncology (ESMO) study reported inequalities in the availability of anticancer medicines...
4.
Moro-Sibilot D, Cozic N, Perol M, Mazieres J, Otto J, Souquet P, et al.
Ann Oncol
. 2019 Oct;
30(12):1985-1991.
PMID: 31584608
Background: In 2013, the French National Cancer Institute initiated the AcSé program to provide patients with secure access to targeted therapies outside of their marketed approvals. Efficacy and safety was...
5.
Rodriguez D, Chambers T, Warmuth-Metz M, Aliaga E, Warren D, Calmon R, et al.
AJNR Am J Neuroradiol
. 2019 Mar;
40(3):568-575.
PMID: 30819765
Background And Purpose: HERBY was a Phase II multicenter trial setup to establish the efficacy and safety of adding bevacizumab to radiation therapy and temozolomide in pediatric patients with newly...
6.
Gaspar N, Marshall L, Binner D, Herold R, Rousseau R, Blanc P, et al.
Ann Oncol
. 2018 Jan;
29(3):766-771.
PMID: 29351570
No abstract available.
7.
Vassal G, Landman-Parker J, Baruchel A, Bergeron C, Rubie H, Coze C, et al.
Arch Pediatr
. 2015 Nov;
22(12):1217-22.
PMID: 26604021
Introduction: According to the European Society of Pediatric Oncology (SIOPE) standard of care guidelines, high-quality care of children and adolescents with cancer needs to be delivered by well-trained multidisciplinary teams...
8.
Karayan-Tapon L, Cortes U, Rivet P, Jermidi C, Vassal G, Wager M, et al.
Eur J Cancer
. 2014 Jul;
50(13):2364-6.
PMID: 24999209
No abstract available.
9.
Veal G, Nguyen L, Paci A, Riggi M, Amiel M, Valteau-Couanet D, et al.
Eur J Cancer
. 2012 Jun;
48(16):3063-72.
PMID: 22742881
Introduction: Busulfan is widely used in a neuroblastoma setting, with several studies reporting marked inter-patient variability in busulfan pharmacokinetics and pharmacodynamics. The current study reports on the pharmacokinetics of oral...
10.
Doussau A, Asselain B, Le Deley M, Geoerger B, Doz F, Vassal G, et al.
Contemp Clin Trials
. 2012 Apr;
33(4):657-65.
PMID: 22521954
Objective: Usual dose-finding methods in oncology are sequential. Accrual is suspended after each group of patients to assess toxicity before increasing the dose. An adapted Continual Reassessment Method (CRM) and...